Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Didanosine EC vs Standard Didanosine in HIV
NCT00002224Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 1999
- Primary completion
- Mar 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of didanosine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Reduction of plasma HIV RNA at 24 weeks. Started Mar 1999; status: completed.
02
Drugs
didanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002224.